New Promising Treatment for Scleroderma Related Interstitial Lung Disease (ILD)
Interstitial lung disease is common in systemic sclerosis and is the leading cause of death. However, there is a new promising treatment for patients suffering from ILD. If discovered early on, prognosis can be positive for patients.
Your childhood and teen years are a prime time to learn habits that will help you keep your bones, joints, muscles and skin healthy for years to come. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIH) is a great resource for updates and features.
Making Progress in Protecting Consumers from Unsafe Supplements
In a previous eLetter, we provided information about how to talk to your doctor about consuming dietary and herbal supplements. The FDA is doing their part to keep you safe. Here is a look at the important steps they have recently taken to protect your health.
Taking care of a loved one with a serious medical condition is certainly a labor of love. Did you know that approximately 43 million adults living in the United States provide unpaid care for someone with a serious health condition? Here is some information to help you also take care of yourself.
Disclaimer: The Scleroderma Foundation in no way
endorses any drugs, treatments, clinical trials, or studies reported in the eLetter. Information is
provided to keep the readers informed. Because the manifestations and severity of scleroderma vary among individuals, personalized medical management is essential. Therefore, it is strongly recommended that all drugs and treatments be discussed with the reader’s physician(s) for proper evaluation and treatment.
The Scleroderma Foundation is a qualified national nonprofit operating under 501(c)(3) status. The foundation’s federal tax identification number is 52-1375827. Our primary goal is to raise funds for our three-fold mission of support, education and research. The foundation has 20 active chapters and 160 support groups across the country.